CRON Stock Analysis: Buy, Sell, or Hold?
CRON - Cronos Group Inc. Common Share
$2.44
-0.06 (-2.40%)
âŧ
5d:
-3.17%
30d:
-8.61%
90d:
-8.27%
WAIT
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
CRON is down 4.4% this week, but smart money is accumulating calls. Top strike: $3 2026-05-15 with 1 OI. Call ratio: 100% View Scanner →
Strength: 7.2/10
Get Alerted When CRON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CRON is fairly priced but lacks strong directional signals. At -2.2% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CRON is fairly priced but lacks strong directional signals. At -2.2% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CRON is currently trading at $2.44, which is considered fair relative to its 30-day fair value range of $2.51 to $2.68. The stock's valuation (Forward PE: 21.0) is in line with its historical norms (22.5). Remarkably, the market is currently pricing in an annual earnings decline of 2.2% over the next few years. This pessimistic expectation contrasts with the company's recent 238.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, CRON is in a strong uptrend. The price is currently testing key support at $2.38. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CRON has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CRON is in a strong uptrend. The price is currently testing key support at $2.38. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CRON has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$2.51 -
$2.68
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
42.9%
Protect Your Profits
Holding CRON? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Trading above Wall St target ($2.27)
Fair Price Analysis
30-Day Fair Range
$2.51 -
$2.68
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$2.38
Resistance Level
$2.67
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
21.03
Wall Street Target
$2.27
(-7.1%)
Revenue Growth (YoY)
47.0%
Earnings Growth (YoY)
238.8%
Profit Margin
-6.5%
Valuation Discount vs History
-2.2% cheaper
PE vs Historical
21.0 vs 22.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.2%
(market-implied from PE analysis)
1-Year Target
$2.39
(-2%)
2-Year Target
$2.33
(-4%)
3-Year Target
$2.28
(-7%)
3-Yr Target (if PE normalizes)
(PE: 21â23)
$2.44
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 30.3%)
$5.74
(+135%)
Base:
(SPY PE: 21.0, Growth: 30.3%)
$5.40
(+121%)
Bear:
(PE: 17.9, Growth: 30.3%)
$4.59
(+88%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 21.0 to 22.5
Stabilization Target:
$2.61
(+7.0%)
PE Expansion Potential:
+7.0%
Share & Embed Analysis
Last updated: March 31, 2026 7:04 AM ET
Data refreshes hourly during market hours. Next update: 8:04 AM
Data refreshes hourly during market hours. Next update: 8:04 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$178 | 63 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 55 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 63 BUY |
|
BCRX
BioCryst PharmaceuticalsâĻ |
STRONG BUY
12 analysts |
$21 | 56 HOLD |
Advanced CRON Option Strategies
Professional options setups generated by AI based on today's CRON price and gamma walls.
